Circulating Interleukin-22 Is a Biomarker for Newly Diagnosed Type 2 Diabetes Mellitus and Associated with Hypoglycemic Effect of Sitagliptin.

Diabetes Metab Syndr Obes · 2025 · PMC11887505 · PMID 40061492

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The detection showed that sitagliptin monotherapy induced a decreasing trend in IL-22 levels, although there was no statistically significant difference (130.1 vs 103.1, p = 0.070, Figure 2A ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.